|4Dec 18, 4:30 PM ET

ALIMERA SCIENCES INC 4

4 · ALIMERA SCIENCES INC · Filed Dec 18, 2013

Insider Transaction Report

Form 4
Period: 2013-12-16
Caballa Susan
SEE REMARKS
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2013-12-16+90,00090,000 total
    Exercise: $2.47Exp: 2023-12-15Common Stock (90,000 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2013-12-16+35,00035,000 total
    Exercise: $2.47Exp: 2023-12-15Common Stock (35,000 underlying)
Footnotes (2)
  • [F1]This option shall vest in forty-eight equal monthly installments beginning on January 16, 2014, provided that the Reporting Person remains continuously employed by the Issuer through each vesting period.
  • [F2]This option shall become exercisable only upon approval by the U.S. Food and Drug Administration of the Issuer's New Drug Application for ILUVIEN(R) for the treatment of diabetic macular edema, provided that such approval occurs on or before December 31, 2014, in which case this option shall vest in forty-eight equal monthly installments beginning on January 16, 2014, provided further that the Reporting Person remains continuously employed by the Issuer through each vesting period.

Documents

1 file
  • 4
    rrd397837.xmlPrimary

    FORM 4